Formed in 2014 by ACPHS President Greg Dewey, the President's Advisory Council (PAC) is comprised of leaders in the corporate, academic, and not-for-profit sectors.
The Council's overarching directive is to offer insights into how educational institutions should respond to long term trends in the health science and health care industries. The group meets twice per year.
Harvey Arbit has more than 30 years of experience in the pharmaceutical industry spanning the areas of regulatory affairs, clinical research, quality control, and product development. In addition to leading the University of Minnesota’s Academic Health Center's IND/IDE Assistance Program, Dr. Arbit also provides FDA regulatory strategy and support for industry, academia, and investigator-initiated clinical research through Arbit Consulting LLC.
Nancy Barbour is vice president of Drug Product Science & Technology at Bristol-Myers Squibb (BMS). In this role, she is responsible for global product and process development for the entire pipeline of small molecules, biological compounds, and devices. Dr. Barbour joined BMS in 1991 after receiving her B.S. in pharmacy from ACPHS and Ph.D. in pharmaceutical chemistry from the University of Kansas.
Rebecca Blanchard is the Vice President of Experimental Medicine at CRISPR Therapeutics. Prior to joining CRISPR, Dr. Blanchard was the head of Clinical Pharmacogenomics within the Human Genetics and Pharmacogenomics department at Merck. Her career in academia and in industry has spanned preclinical, translational, and clinical development across multiple therapeutic areas.
Robert Blum co-founded Buffalo Clinical Research Center, LLC (BCRC) in 2001. BCRC is a state-of-art Phase I research facility assisting pharmaceutical companies with early phase drug development. BCRC engages in a wide range of research activities including “first-time-in-man” safety, tolerability and pharmacokinetic/ pharmacodynamic studies, bioavailability/ bioequivalence, drug interaction, gender-and food-effect studies.
Mac Bonafede is the Director of the Outcomes Research group of Truven Health Analytics (formerly Thomson Reuters Healthcare). He has extensive experience in the areas of healthcare research, education, and consulting. Before joining Truven Health, Dr. Bonafede served on the faculty at Albany College of Pharmacy and Health Sciences, where he taught courses covering research and statistical methods, total quality management, and evidence-based medicine.
David Carpenter is the Senior Director, Clinical Research and Development at Altavant Sciences. Altavant is a wholly owned subsidiary of Roivant Pharma which is focused on accelerating the development of novel therapeutic agents to improve outcomes in the treatment of pulmonary and cardiovascular disorders. He previously held senior leadership roles at Dart Neuroscience, GlaxoSmithKline, and Sanofi Pharmaceuticals.
Christopher Conway is Senior Vice President, Head of Drug Discovery, Chemical Development, and Analytical Services at Albany Molecular Research, Inc. Prior to joining AMRI, Mr. Conway held sales, marketing, and leadership positions at Johnson & Johnson, where he completed J&J’s Leadership Development Program and received both Johnson & Johnson’s Global Standards of Leadership and Global Innovation Awards.
As the Vice President, Market Access, Distribution and Patient Access Services at Incyte Corporation, Joseph Cordaro is responsible for leading commercial functions and field teams responsible for Payer National Accounts, Strategic Accounts, Distribution, Patient Access Services, and Channel Marketing for current and future products. Prior to joining Incyte, Dr. Cordaro held leadership positions with AstraZeneca, Roche Pharmaceuticals, and Novartis Pharmaceuticals Corporation.
Chris Dadas is the National Director for the Urology Medical Liaison Team at Allergan, Inc. His work fully integrates medical communications from many internal and external stakeholders, driving corporate research strategy and scientific direction. Prior to being promoted to his current position, Dr. Dadas served in a variety of roles at Allergan including Director of Medical Affairs Operations and Director of Neurosciences Medical Liaisons.
Dr. Diliberto has more than 44 years of academic, pharmaceutical industry, and government R&D experience. His past positions have included serving as Professor & Chair of the Department of Pharmaceutical Sciences at Campbell University College of Pharmacy & Health Sciences and Group Leader in the Molecular and Cellular Pharmacology Section in the Pharmacology Division at Burroughs Wellcome Co.
Chris Di Lascia is the President, CEO, and co-founder of Transition Patient Services (TPS). He was previously employed with Aventis Pharmaceuticals where he held the position of Global Marketing Director for Lovenox. He began his pharmaceutical industry career as a Hospital Sales Representative with Eli Lilly and Company before leaving to join Schering-Plough as a Managed Care and Government Affairs Manager.
Tanya Dumrongmanee has a decade of experience bringing operational efficiencies to industries such as e-commerce, higher education, information technology, and manufacturing, having most recently served in a product engineering role at EMC Corporation. Past projects have included ERP system implementation, supply chain management process development, and Series C funding.
Clayton Edwards is the Senior Vice President, Mail Service Operations for OptumRx where he oversees a team of more than 3,000 employees in five locations across the country that dispenses more than 30 million prescriptions annually. Prior to joining OptumRx, he served as senior vice president, Chief Pharmacy Officer with Sanari and as president of Rhema Healthcare Consulting, specializing in all aspects of PBM management, pharmacy fulfillment, and health care marketing.
Seve Falati is a registered patent attorney and Managing Partner of Albany-based FALATI Intellectual Property Law & Management Consultancy firm, where he leads a group of seven intellectual property law attorneys. His clients include U.S. and foreign based entities with interests in new and emerging technologies. In addition to his law degree, he has a Ph.D. in Pharmacology and completed a three-year Postdoctoral Fellowship at Harvard Medical School / Beth Israel Deaconess Medical Center.
As the Chief Communications and Public Relations Officer at CareFully Inc., Helen Figge is responsible for helping to build and sustain the company's reputation for quality, reliability, and customer satisfaction. She previously served as an executive with three Fortune 500 companies in addition to being a member of the senior leadership team at the Health Information Management Systems Society (HIMSS). She has been named one of the "Most Powerful Women in Healthcare IT" three times by Health Data Management.
Tom Garcia is a Research Fellow in the Global Chemistry, Manufacturing, and Controls (GCMC) group at Pfizer Inc. In this role, he works with cross-functional teams to define development and regulatory strategies that generate the data required for the preparation and submission of global NDAs/MAAs, as well as responses to regulatory queries and observations. The first 14 years of his career were spent doing process development and technology transfer.
After earning both her Doctor of Pharmacy (Pharm.D.) and M.S. in Pharmaceutical Sciences from ACPHS, Jaclyn began working at Regeneron Pharmaceuticals in 2012 and currently serves in the role of Manager, CMC Project Management. Her previous positions at Regeneron have included Senior Manufacturing Process & Technology Associate and Associate Manager, Technology Transfer.
Frank Grosso is the Executive Director and CEO of the American Society of Consultant Pharmacists. He has 35 years of Long Term Care Pharmacy experience, including serving as Vice President of Pharmacy Services for Genesis Healthcare, a long term care provider. His responsibilities at Genesis included oversight of the operational and contracted pharmacy services for 411 Nursing Centers and Assisted Living Communities.
Marylee Grosso is Managing Partner, HealthCare Consults, LLC, an independent consulting company that addresses the challenges faced by post-acute care providers, vendors, and professional organizations in a rapidly changing regulatory and reimbursement environment. Prior to her current role, she served as Corporate Senior Director of Clinical Operations for Genesis Healthcare, overseeing the clinical pharmacy practice standards of the Nursing and Medical Affairs Departments in over 500 centers.
Gary Hollenbeck has had an extended career in pharmaceutical science and education, including approximately 30 years in academia and 10 years in the industry. He served as Professor of Pharmaceutical Sciences and Associate Dean for Academic Programs at the University of Maryland School of Pharmacy. He was also a principal figure in the formation and development of UPM Pharmaceuticals, Inc., eventually joining the company full time as Chief Scientific Officer.
Stephen Hulse is the Regional Sales Director at Genentech, one of the world's leading biotechnology companies. He has 25+ years of experience in the pharmaceutical industry, including extensive management expertise at the district, regional, and national levels. He is an experienced marketer of several major branded franchises, including international strategic development, and domestic business development initiatives.
David Kvancz is Senior Vice President, Strategic Client Relationships at Visante, a healthcare consulting firm with a focus on medication use and system optimization. Before joining Visante, Mr. Kvancz served as Vice President of National Pharmacy Programs and Services for Kaiser Permanente and, prior to that experience, he was the Chief Pharmacy Officer for the Cleveland Clinic Health System.
Jonathan Lasch is the Executive Director for the Alfred E. Mann Institute for Biomedical Engineering at the University of Southern California (AMI-USC). He has more than 25 years of experience in science and technology development and evaluation in the fields of biomedical instruments and systems, biotechnology, chemistry, and materials science. Prior to joining AMI-USC, Dr. Lasch served as a Managing Director of Convergent Ventures, an early stage life sciences venture investment and development company.
Stephen McCormack is passionate about the development of medical products, technologies, and services that address unmet medical needs. He currently serves as Chairman of the Board of Directors and Chief Executive Officer of Visus Technology, a company developing cloud-based computer vision solutions for the elderly and visually impaired communities. His scientific contributions and patents include delivery of drugs to the eye, medical devices for the treatment of tinnitus, and diagnostic tests for cervical cancer.
Wallace Pickworth is a pharmacologist with extensive preclinical and clinical experience. He was with NIH for nearly 30 years from a post-doc position to a tenured staff scientist at the National Institute on Drug Abuse. For the past ten years, Dr. Pickworth has directed clinical research on tobacco and nicotine for Battelle as a Research Leader. He holds licenses to practice pharmacy in two states, works part-time in a hospital pharmacy, and serves as an adjunct faculty at two colleges of pharmacy.
Samantha Schwall is the Director of Program and Field Service Operations - Americas at Laerdal Medical. She previously served as the Director of Business Innovation at Boehringer Ingelheim where she helped manage key strategic partnerships to help transform the development and commercialization of products across the entire lifecycle and value chain. She also has experience in the areas of Pharmacy Marketing, Drug Information and Surveillance, and Respiratory Medical Affairs.
Mr. Ullmann brings leadership, experience, and skills as an executive manager with a unique background in both private and public sectors of the health care and wellness industries. He has developed more than 30 start-up companies, and for 16 years served as the Founder, Chairman, President, and Chief Executive Officer of a publicly-traded New York-based health management company (Wellcare) which developed and managed six operating HMOs.